Bispecific monoclonal antibody

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Retrieved on: 
Monday, September 26, 2022
YouTube, Therapy, LAVA, Target, Safety, COVID-19, Twitter, ADC, Colorectal cancer, Intention, LinkedIn, Company, Growth, Bispecific monoclonal antibody, Partnership, Forward-looking statement, Chief medical informatics officer, U.S. Securities and Exchange Commission, Survival, Patient, Lung cancer, Potential, Cancer, Activate, CEO, Technology, Lutheran Student Fellowship, Cell, Nasdaq, Head, Monoclonal antibody, Research, Trade, Security (finance), GLOBE, Union, EGFR, Vaccine, Fine chemical, Pharmaceutical industry, Seagen

BOTHELL, Wash. and UTRECHT, The Netherlands and PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA’s proprietary Gammabody™ technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors.

Key Points: 
  • LAVA-1223 is an advanced preclinical asset that utilizes LAVAs proprietary Gammabody technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors.
  • The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody platform on up to two additional tumor targets.
  • This exclusive license from LAVA provides Seagen with the opportunity to harness its expertise in developing first-in-class targeted cancer therapies, along with the companys global development and commercialization capabilities.
  • LAVA is pioneering the development of gamma delta bispecific antibodies to treat cancer, and we are pleased to work with Seagen in this pursuit.

Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, CD25, ADCC, MOA, Bispecific monoclonal antibody, Neoplasm, Mab, Antigen, Research, Innovation, Vaccine, Regulatory T cell

Invenra, a company developing next generation therapeutic antibodies, announced today that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic.

Key Points: 
  • Invenra, a company developing next generation therapeutic antibodies, announced today that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic.
  • The presentation will highlight preclinical data related to the lead candidate INV322, a SNIPER Bispecific Antibody co-targeting CTLA-4 and CD25.
  • In vitro studies have characterized avidity-mediated binding of INV322 to these tumor Treg antigens as well as an antibody dependent cell cytotoxicity (ADCC) mediated mode of action.
  • We are very pleased with the strong preclinical data that our research team has generated with INV322 using our proprietary multispecific B-Body Platform.

Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress

Retrieved on: 
Monday, September 12, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Paris Expo Porte de Versailles, Safety, Breast, Engineering, COVID-19, Twitter, ADC, NYSE, Interest, FACP, Company, Inc., European Society for Medical Oncology, Review, Bispecific monoclonal antibody, HER2, Forward-looking statement, U.S. Securities and Exchange Commission, Patient, Oncology, Biliary tract, First grade, EST, Private Securities Litigation Reform Act, Drug development, Lung, Research, Security (finance), Congress, Memorial Sloan Kettering Cancer Center, Conjugation, Cancer, ESMO, Pharmaceutical industry, MD, Zymeworks

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the companys Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the companys Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors.
  • Commenting on the data, Dr. Jhaveri noted, The preliminary results of this trial are very encouraging.
  • Zanidatamab zovodotin dosed on an every three week (Q3W) schedule is active and has a manageable safety profile.
  • In the trial, zanidatamab zovodotin was shown to have a manageable safety profile with the majority of adverse events being Grade 1 or 2 in severity.

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

Retrieved on: 
Monday, September 12, 2022
CFO, Plan, Compugen, Statistics, Honours degree, Business administration, TIGIT, TASE, Eleazar Sukenik, Company, Growth, Amdocs, Industry, Immunotherapy, Patient, Anat, M&A, Cancer, TEL, Hebrew University of Jerusalem, AstraZeneca, Nasdaq, Leadership, Crown Worldwide Group, Tumor microenvironment, Research, Bispecific monoclonal antibody, Pharmaceutical industry, Management, Bayer

HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team.

Key Points: 
  • HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team.
  • "I am delighted to have a financial executive of Alberto's expertise and experience join Compugen and strengthen our management team," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.
  • Alberto brings more than 30 years of industry experience to Compugen by serving in public and private companies.
  • Previously, Alberto spent seven years as Worldwide Group CFO at Nasdaq listed Amdocs with responsibility for the global financial business activities.

Compugen to Participate in Upcoming Fierce Biotech Summit

Retrieved on: 
Wednesday, September 7, 2022
AstraZeneca, Machine learning, Compugen, Research, Tumor microenvironment, Artificial intelligence, SVP, Senior, Nasdaq, Company, Immunotherapy, Bispecific monoclonal antibody, TIGIT, Senior advisor, TEL, Drug development, Pharmaceutical industry, Bayer

YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and accelerate drug development.

Key Points: 
  • YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and accelerate drug development.
  • HOLON, Israel, Sept. 7, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN),a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,announced today, that Yaron Turpaz, Ph.D., Senior Vice President and Senior Advisor, Computational Discovery at Compugenwill participate in a panel at the Fierce Biotech Summit taking place from 20 to 21 September 2022, in Boston, United States.
  • The most advanced program, a high affinity antibody, COM503 with first-in-class potential is about to enter pre-IND enabling studies.
  • COM503 targets a soluble immune checkpoint upregulated in the tumor microenvironment in response to IFN-.

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

Retrieved on: 
Sunday, September 4, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Security (finance), COVID-19, FACP, Breast, CEO, Keratitis, Diarrhea, Hair, NYSE, Safety, Interest, Research, Death, Engineering, Paris Expo Porte de Versailles, EST, Chair, Conjugation, ESMO, Clinical Oncology, Interstitial lung disease, Memorial Sloan Kettering Cancer Center, U.S. Securities and Exchange Commission, HER2, Inc., Cancer, Twitter, Trae tha Truth, CEST, ADC, Bispecific monoclonal antibody, Webcast, Private Securities Litigation Reform Act, Drug development, Forward-looking statement, Patient, Fine chemical, Pharmaceutical industry, Zymeworks, MD

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the release of an abstract by ESMO with preliminary results from the companys Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the release of an abstract by ESMO with preliminary results from the companys Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate.
  • Among seven patients who experienced TRAEs of grade 3 or higher, two were grade 4 events including infusion-related reaction and decreased neutrophil count.
  • There were three patient discontinuations associated with TRAEs and no reported treatment-related patient deaths or cases of interstitial lung disease.
  • We are excited to share our preliminary results from the ongoing Phase 1 study at ESMO, said Kenneth Galbraith, Chair and CEO of Zymeworks.

Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan

Retrieved on: 
Wednesday, August 24, 2022
AstraZeneca, Compugen (Israeli company), Security (finance), COVID-19, Research, Compugen, Securities Exchange Act of 1934, Securities Act of 1933, Tumor microenvironment, PVRL2, Private Securities Litigation Reform Act, Risk, Forward-looking statement, SEC, U.S. Securities and Exchange Commission, Patent, PD-1, Japan Patent Office, Nasdaq, Company, Immunotherapy, Bispecific monoclonal antibody, TIGIT, Terminology, Annual report, Method, TEL, Patient, Pharmaceutical industry, Bayer, PVRIG

2017-562952, titled "Anti-PVRIG antibodies and Methods of Use" augments previously issued patents by expanding and protecting COM701 beyond Europe and the U.S. to include coverage in Japan.

Key Points: 
  • 2017-562952, titled "Anti-PVRIG antibodies and Methods of Use" augments previously issued patents by expanding and protecting COM701 beyond Europe and the U.S. to include coverage in Japan.
  • COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.
  • Forward-looking statements include, but are not limited to, statements regarding the expected expiration date of the patent inJapan.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Worldwide Clinical Trials Expands Global Footprint of Large Molecule Services with New Lab at Bioanalytical Center of Excellence

Retrieved on: 
Tuesday, August 23, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Pharmacokinetics, Research, Degenerative disease, Worldwide, Vaccine, Mab, USD, Physician, Neuroscience, Investment, Pharmacology, Biotechnology, CAGR, Biomarker, ADA, Bispecific monoclonal antibody, ADC, Clinical trial, Growth, General manager, CRO, Fine chemical, Pharmaceutical industry

Worldwide Clinical Trials, Inc. ( Worldwide), the industrys leading global, midsize, full-service contract research organization (CRO), has expanded its Early Phase large molecule capabilities and services with a new 15,000 square foot dedicated lab at its multimillion dollar Bioanalytical Center of Excellence in Austin, Texas.

Key Points: 
  • Worldwide Clinical Trials, Inc. ( Worldwide), the industrys leading global, midsize, full-service contract research organization (CRO), has expanded its Early Phase large molecule capabilities and services with a new 15,000 square foot dedicated lab at its multimillion dollar Bioanalytical Center of Excellence in Austin, Texas.
  • The global large molecule bioanalytical testing services market was valued at USD 1.4 billion in 2020 and is expected to experience a compound annual growth rate (CAGR) of 9.5% until 2028 ( source ).
  • Driving this growth are increasingly complex innovations in the healthcare sector, causing the demand for quality and technologically advanced large molecule bioanalytical testing services to expand at a rapid rate.
  • Worldwide Clinical Trials is a global, midsize contract research organization (CRO) that provides top-performing bioanalytical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries.

Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio

Retrieved on: 
Monday, August 8, 2022
Compugen, European Patent Convention, TIGIT, Securities Act of 1933, U.S. Securities and Exchange Commission, Forward-looking statement, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, SEC, Cancer, Terminology, NK, European Patent Office, PD-1, Patent, Security (finance), Research, Annual report, Patient, COVID-19, Company, Tumor microenvironment, PVRL2, Bispecific monoclonal antibody, NASDAQ, Risk, Method, Immunotherapy, Nasdaq, AstraZeneca, TEL, Compugen (Israeli company), Pharmaceutical industry, Vaccine, Bayer, PVRIG

COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.

Key Points: 
  • COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, blocking the interaction with its ligand, PVRL2.
  • Compugen has identified PVRIG and TIGIT as key parallel and complementary inhibitory pathways in the DNAM-1 axis, which also intersect with the well-established PD-1 pathway.
  • Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Retrieved on: 
Friday, August 5, 2022
Antibody, U.S. Securities and Exchange Commission, Risk, Pierre Geneves, BioNTech, Technology, Private Securities Litigation Reform Act, SEC, Cancer, Regeneron Pharmaceuticals, CD27, BNTX, Research, Annual report, Environment, NSCLC, Hoffmann-La Roche, Patient, Review, Risk management, Company, Large-cell lung carcinoma, Infection, Program, Biotechnology, Safety, Bispecific monoclonal antibody, Nature, Immunotherapy, Nasdaq, Cell membrane, RNA transfection, Pharmaceutical industry, Vaccine, Genentech, Pfizer, Genmab

MAINZ, Germany, and COPENHAGEN, Denmark, August 5, 2022 BioNTech SE (Nasdaq: BNTX, BioNTech) and Genmab A/S (Genmab) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.

Key Points: 
  • MAINZ, Germany, and COPENHAGEN, Denmark, August 5, 2022 BioNTech SE (Nasdaq: BNTX, BioNTech) and Genmab A/S (Genmab) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.
  • Under this expansion, BioNTech and Genmab will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.
  • Strategic partnerships, like our collaboration with BioNTech, are critical to developing differentiated antibody medicineswith the aim of improving the lives of cancer patients.
  • Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo;HuMax;DuoBody;DuoBodyin combination with theDuoBodylogo;HexaBody;HexaBodyin combination withtheHexaBodylogo;DuoHexaBody andHexElect.